A Phase I/II Study for Analytic Validation of Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer
نویسندگان
چکیده
Neeta Pandit-Taskar, Joseph A. O’Donoghue, Jeremy C. Durack, Serge Lyashchenko, Sarah M. Cheal, Volkan Beylergil, Robert A. Lefkowitz, Jorge A. Carrasquillo, Danny F. Martinez, Alex Mak Fung, Stephen B. Solomon, Mithat Gönen, Glenn Heller, Massimo Loda, David Nanus, Scott Tagawa, Jarett L. Feldman, Joseph R. Osborne, Jason S. Lewis, Victor E. Reuter, Wolfgang A. Weber, Neil H. Bander, Howard I. Scher, Steven M. Larson, Michael J. Morris
منابع مشابه
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.
PURPOSE Standard imaging for assessing osseous metastases in advanced prostate cancer remains focused on altered bone metabolism and is inadequate for diagnostic, prognostic, or predictive purposes. We performed a first-in-human phase I/II study of (89)Zr-DFO-huJ591 ((89)Zr-J591) PET/CT immunoscintigraphy to assess performance characteristics for detecting metastases compared with conventional ...
متن کاملPhase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.
PURPOSE To assess the efficacy of a single infusion of radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (lutetium-177; (177)Lu) by prostate-specific antigen (PSA) decline, measurable disease response, and survival. EXPERIMENTAL DESIGN In this dual-center phase II study, two cohorts with progressive metastatic castration-resistant prostate cancer received on...
متن کاملQuantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody.
UNLABELLED Prostate stem cell antigen (PSCA) is expressed on the cell surface in 83%-100% of local prostate cancers and 87%-100% of prostate cancer bone metastases. In this study, we sought to develop immunoPET agents using (124)I- and (89)Zr-labeled anti-PSCA A11 minibodies (scFv-CH3 dimer, 80 kDa) and evaluate their use for quantitative immunoPET imaging of prostate cancer. METHODS A11 anti...
متن کاملPhase IIa Clinical Trial of Trans-1-Amino-3-18F-Fluoro- Cyclobutane Carboxylic Acid in Metastatic Prostate Cancer
Objective(s): We performed a phase IIa clinical trial of trans-1-amino-3-18Ffluoro-cyclobutane carboxylic acid (anti-18F-FACBC), a synthetic amino acid analog for PET, in patients with metastatic prostate cancer. Methods: The study subjects consisted of 10 untreated prostate cancer patients having lymph node and/or bone metastasis. Five patients underwent whole-body PET 5 and 30 min after intra...
متن کاملTargeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling
BACKGROUND We applied a non-linear immunokinetic model to quantitatively compare absolute antibody uptake and turnover in subcutaneous LNCaP human prostate cancer (PCa) xenografts of two radiolabeled forms of the humanized anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 ((124)I-J591 and (89)Zr-J591). Using the model, we examined the impact of dose on the tumor and plasma...
متن کامل